AU2004222825B2 - Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response - Google Patents
Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response Download PDFInfo
- Publication number
- AU2004222825B2 AU2004222825B2 AU2004222825A AU2004222825A AU2004222825B2 AU 2004222825 B2 AU2004222825 B2 AU 2004222825B2 AU 2004222825 A AU2004222825 A AU 2004222825A AU 2004222825 A AU2004222825 A AU 2004222825A AU 2004222825 B2 AU2004222825 B2 AU 2004222825B2
- Authority
- AU
- Australia
- Prior art keywords
- carbon atoms
- inclusive
- branched
- straight
- hydrogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229930184725 Lipoxin Natural products 0.000 title claims description 93
- 210000000440 neutrophil Anatomy 0.000 title description 31
- -1 lipoxin compounds Chemical class 0.000 title description 22
- 230000004044 response Effects 0.000 title description 9
- 230000002401 inhibitory effect Effects 0.000 title description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 136
- 150000002639 lipoxins Chemical class 0.000 claims description 82
- 125000000217 alkyl group Chemical group 0.000 claims description 62
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 47
- 206010061218 Inflammation Diseases 0.000 claims description 38
- 230000004054 inflammatory process Effects 0.000 claims description 38
- 102000004127 Cytokines Human genes 0.000 claims description 36
- 108090000695 Cytokines Proteins 0.000 claims description 36
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 32
- 229910052736 halogen Inorganic materials 0.000 claims description 30
- 150000002367 halogens Chemical class 0.000 claims description 30
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 28
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 28
- 125000003342 alkenyl group Chemical group 0.000 claims description 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 20
- 206010048768 Dermatosis Diseases 0.000 claims description 17
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 17
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 17
- 208000017520 skin disease Diseases 0.000 claims description 17
- 208000001840 Dandruff Diseases 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 13
- 102000003816 Interleukin-13 Human genes 0.000 claims description 12
- 108090000176 Interleukin-13 Proteins 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 108700012920 TNF Proteins 0.000 claims 8
- 101500021084 Locusta migratoria 5 kDa peptide Proteins 0.000 claims 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims 1
- 235000009685 Crataegus X maligna Nutrition 0.000 claims 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims 1
- 235000009486 Crataegus bullatus Nutrition 0.000 claims 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims 1
- 235000009682 Crataegus limnophila Nutrition 0.000 claims 1
- 235000004423 Crataegus monogyna Nutrition 0.000 claims 1
- 240000000171 Crataegus monogyna Species 0.000 claims 1
- 235000002313 Crataegus paludosa Nutrition 0.000 claims 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 87
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 85
- 150000001875 compounds Chemical class 0.000 description 68
- 239000000203 mixture Substances 0.000 description 29
- 230000000694 effects Effects 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 102000004388 Interleukin-4 Human genes 0.000 description 23
- 108090000978 Interleukin-4 Proteins 0.000 description 23
- 238000001727 in vivo Methods 0.000 description 19
- 108010002352 Interleukin-1 Proteins 0.000 description 18
- 102000000589 Interleukin-1 Human genes 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- 210000000265 leukocyte Anatomy 0.000 description 16
- 239000008194 pharmaceutical composition Substances 0.000 description 16
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 14
- 229960001138 acetylsalicylic acid Drugs 0.000 description 14
- 230000003110 anti-inflammatory effect Effects 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 239000003981 vehicle Substances 0.000 description 14
- IXAQOQZEOGMIQS-ORRYEOPJSA-N Lipoxin A Natural products CCCCCC(O)C=CC=C/C=C/C=C/C(O)C(O)CCCC(=O)O IXAQOQZEOGMIQS-ORRYEOPJSA-N 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- IXAQOQZEOGMIQS-SSQFXEBMSA-N lipoxin A4 Chemical compound CCCCC[C@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCCC(O)=O IXAQOQZEOGMIQS-SSQFXEBMSA-N 0.000 description 13
- 230000003389 potentiating effect Effects 0.000 description 13
- 102100021126 N-formyl peptide receptor 2 Human genes 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 210000000416 exudates and transudate Anatomy 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 12
- 101000818546 Homo sapiens N-formyl peptide receptor 2 Proteins 0.000 description 11
- 101000931587 Mus musculus Formyl peptide receptor-related sequence 1 Proteins 0.000 description 11
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 10
- 230000009471 action Effects 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000008595 infiltration Effects 0.000 description 9
- 238000001764 infiltration Methods 0.000 description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 description 9
- 230000009466 transformation Effects 0.000 description 9
- 241001529936 Murinae Species 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 230000002503 metabolic effect Effects 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 102000019034 Chemokines Human genes 0.000 description 7
- 108010012236 Chemokines Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 208000038016 acute inflammation Diseases 0.000 description 6
- 230000006022 acute inflammation Effects 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 150000002617 leukotrienes Chemical class 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 102000018832 Cytochromes Human genes 0.000 description 5
- 108010052832 Cytochromes Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
- 102000003814 Interleukin-10 Human genes 0.000 description 5
- 108090000174 Interleukin-10 Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 229920000392 Zymosan Polymers 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000000975 bioactive effect Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 description 5
- 230000010410 reperfusion Effects 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000001960 triggered effect Effects 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 4
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000005754 cellular signaling Effects 0.000 description 4
- 230000035605 chemotaxis Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 150000002066 eicosanoids Chemical class 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000004941 influx Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000006072 paste Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000010487 tragacanth Nutrition 0.000 description 4
- 239000000196 tragacanth Substances 0.000 description 4
- 229940116362 tragacanth Drugs 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- UXVRTOKOJOMENI-ICTGYCPSSA-N (6e,8e,10e,12e)-5,14,15-trihydroxyicosa-6,8,10,12-tetraenoic acid Chemical compound CCCCCC(O)C(O)\C=C\C=C\C=C\C=C\C(O)CCCC(O)=O UXVRTOKOJOMENI-ICTGYCPSSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010018364 Glomerulonephritis Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 201000008269 immune-complex glomerulonephritis Diseases 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 229940028885 interleukin-4 Drugs 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 208000037816 tissue injury Diseases 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- IXAQOQZEOGMIQS-JEWNPAEBSA-N 15-epi-lipoxin A4 Chemical compound CCCCC[C@@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCCC(O)=O IXAQOQZEOGMIQS-JEWNPAEBSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 102000001902 CC Chemokines Human genes 0.000 description 2
- 108010040471 CC Chemokines Proteins 0.000 description 2
- 108050006947 CXC Chemokine Proteins 0.000 description 2
- 102000019388 CXC chemokine Human genes 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000721179 Clarias Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 206010015866 Extravasation Diseases 0.000 description 2
- 108010076288 Formyl peptide receptors Proteins 0.000 description 2
- 102000011652 Formyl peptide receptors Human genes 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 2
- 101150084044 P gene Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 230000010799 Receptor Interactions Effects 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000002514 anti-leishmanial effect Effects 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 230000036251 extravasation Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 210000000224 granular leucocyte Anatomy 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000008611 intercellular interaction Effects 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 210000003622 mature neutrocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000013081 microcrystal Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 201000004595 synovitis Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000006441 vascular event Effects 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- UXGXCGPWGSUMNI-BVHTXILBSA-N 5(S),15(S)-DiHETE Chemical compound CCCCC[C@H](O)\C=C\C=C/C\C=C/C=C/[C@@H](O)CCCC(O)=O UXGXCGPWGSUMNI-BVHTXILBSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 101710091942 N-formyl peptide receptor 2 Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 description 1
- 101710155454 Sphingosine 1-phosphate receptor 1 Proteins 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001517 counterregulatory effect Effects 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000006539 extracellular acidification Effects 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940047127 fiore Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000013198 immunometric assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000018276 interleukin-1 production Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- UXVRTOKOJOMENI-WLPVFMORSA-N lipoxin B4 Chemical compound CCCCC[C@H](O)[C@H](O)\C=C\C=C\C=C/C=C/[C@@H](O)CCCC(O)=O UXVRTOKOJOMENI-WLPVFMORSA-N 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 229940095673 shampoo product Drugs 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229940095696 soap product Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
P001 Section 29 Regulation 3.2(2)
AUSTRALIA
Patents Act 1990 COMPLETE SPECIFICATION STANDARD PATENT Application Number: Lodged: Invention Title: Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response The following statement is a full description of this invention, including the best method of performing it known to us: 0 USE OF LIPOXIN COMPOUNDS FOR INHIBITING OF TNF-(ALFA) INITIATED NEUTROPHIL RESPONSE S BACKGROUND OF THE INVENTION O Lipid and protein mediators of inflammation such as cytokines and chemokines C N have a profound impact on the formation and actions of each other (Serhan,.C.N., HaeggstrOm, and C.C. Leslie. 1996. Lipid mediator networks in cell signaling: update and 0 impact of cytokines. FASEB J. 10:1147-1158). In particular, the cytokines TNFa and IL- O0 S1P1 play major roles in inflammation, septic shock and tissue injury. PMN perform a range 4 of well-appreciated specialized functions, including chemotaxis, generation of reactive Soxygen species and biosynthesis of potent lipid mediators (Weiss, S.J. 1989. Tissue destruction by neutrophils. N. Engl. J Med. 320:365-376). In this regard, TNFa stimulates PMN to transcribe and release cytokines such as IL- P, enhances leukotriene biosynthesis, and up-regulates adhesion molecules (Marucha, R.A. Zeff, and D.L.
Kreutzer. 1991. Cytokine-induced IL-11 gene expression in the human polymorphonuclear leukocyte: transcriptional and post-transcriptional regulation by tumor necrosis factor and IL-1. J Immunol. 147:2603-2608). Since PMN represent approximately 70% of the peripheral blood leukocytes and are in many instances the initial cell type recruited to interstitial sites, they are now considered a significant source of"proinflammatory" cytokines including TNFa and IL-11. These as well as other PMN-derived cytokines and chemokines can, in turn, affect the course of inflammatory and immune responses (Lloyd, and J.J. Oppenheim. 1992. Poly's lament: the neglected role of the polymorphonuclear neutrophil in the afferent limb of the immune response. Immunology Today 13:169-172). In certain clinical settings, including respiratory distress syndrome, myocardial reperfusion injury, gout and rheumatoid arthritis, PMN contribute to ongoing damage of host tissues (Weiss, S.J. 1989. Tissue destruction by neutrophils. N. Engl. J. Med. 320:365-376; Hachicha, P.H. Naccache, and S.R. McColl. 1995. Inflammatory microcrystals differentially regulate the secretion of macrophage inflammatory protein-1 and interleukin-8 by human neutrophils: A possible mechanism of neutrophil recruitment to sites of inflammation in synovitis. J Exp. Med. 182:2019-2025; Hansen, P.R. 1995. Role of neutrophils in myocardial ischemia and reperfusion. Circulation 91:1872-1885). Thus, it is of interest to understand the complex relationships between lipid mediators and TNFa-evoked PMN responses in order to gain insight for new approaches in controlling these events.
SUMMARY OF THE INVENTION The present invention pertains to methods for modulating a disease or condition associated with TNFa initiated polymorphoneutrophil (PMN) inflammation. The methods include administration to a subject, an effective anti-inflammatory amount of a lipoxin analog having the formula described infra, such that the TNFa initated PMN inflammation is modulated.
The present invention also pertains to methods for treating TNFa initiated polymorphoneutrophil (PMN) inflammation in a subject. The methods include administration of an effective anti-inflammatory amount of a lipoxin analog described infra, such that TNFa initiated polymorphoneutrophil (PMN) inflammation is treated.
The present invention further pertains to methods for modulating a disease or condition associated with TNF initiated cytokine activity in a subject. The methods include, administration of an effective anti-TNFa amount of a lipoxin analog described infra, such that a disease or condition associated with TNFa initiated cytokine activity, is modulated.
The present invention further relates to methods for treating TNFc initiated cytokine activity in a subject. The methods include administration of an effective anti- TNFa amount of a lipoxin analog described infra, such that TNFa initiated cytokine activity, inflammation, is treated.
The present invention also relates to methods for modulating a disease or condition associated with TNFa initiated IL-1P activity in a subject. The methods include administration of an effective anti-inflammatory amount of a lipoxin analog described infra, such that a disease or condition associated with TNFa initiated IL-1p, is modulated.
The present invention further pertains to methods for treating TNFa initiated ILlp activity in a subject. The methods include administration of an effective anti-TNFa amount of a lipoxin analog described infra, such that TNFa initiated IL-1 activity, inflammation, is treated.
In preferred embodiments, the methods of the invention are performed in vitro or in vivo.
In another aspect, the present invention is directed to a packaged pharmaceutical composition for treating a the activity or conditions listed above in a subject. The packaged pharmaceutical composition includes a container holding a therapeutically effective amount of at least one lipoxin compound having one of the formulae described Q infra and instructions for using the lipoxin compound for treating the activity or condition in the subject.
t BRIEF DESCRIPTION OF THE DRAWINGS 00 The invention will be more fully understood from the following detailed Sdescription taken in conjunction with the accompanying drawings, in which: Figure 1 shows that LXA 4 and ATL stable analogs inhibit TNFa-stimulated S superoxide generation by human neutrophils. Human PMN were incubated with either vehicle alone or indicated concentrations of LXA 4 15 R/S-methyl-LXA 4 or 16-phenoxy-
LXA
4 for 5 min and then with TNFc (50 ng/ml) for an additional 10 min. Values are the mean SEM for LXA, 15 R/S-methyl-LXA 4 or 16-phenoxy-LXA 4
LXA
4 and analogs, at all concentrations tested, led to a statistically significant inhibition of TNFa-induced IL- P appearance (p<0.01).
Figure 2 shows that LXA 4 and stable analogs inhibit TNFa-induced IL-1 production in human neutrophils. A) PMN were incubated (TNFa (10 ng/ml) plus vehicle or TNFa plus LXA 4 (100 nM)) as denoted for 20 h at 37 °C and 5% CO,.
Supematants were collected, and IL-1 P was quantitated by ELISA. Results are expressed as mean SD of duplicates, and are from one experiment representative of n=3. B) PMN were incubated for indicated periods of time in the presence of increasing concentrations of 15 R/S-methyl- LXA4. Values represent the mean SEM, n=3. At all time intervals tested, TNFa induced a significant appearance of IL-1 P over vehicle-treated cells Figure 3 demonstrates 15 R/S-methyl-LXA 4 downregulates TNFa-triggered
IL-
I p gene expression. PMN were incubated with either 0.1% ethanol (vehicle) or 15 R/Smethyl-LXA 4 at 10, 100, and 1000 nM, in the presence or absence of TNFa (1Ong/ml), for 6 h at 37 Northern blots were performed in order to detect IL-1I messenger RNA.
The results presented are from one experiment which is representative of two others performed with different donors.
S Figure 4 depicts the involvement of the LXA 4 receptor. PMN were incubated with either IgG purified from pre-immune serum (50 ,giml) or anti-LXA, receptor 0 .g/ml) for 1 h at 4 then exposed to agonists for 12 h at 37 'C and 5% CO,. Values are expressed as mean SD from an experiment performed in triplicate, which is representative of three distinct experiments each performed with different donors tn OO Figure 5 shows the inhibition of TNFa-induced PMN infiltration in murine air pouches. One ml of sterile PBS containing either 0.1% ethanol, TNrFa, 15 R/S-methyl- X LXA 4 or TNFa plus 15 R/S-methyl-LXA 4 was injected into the pouches, and the I exudates were collected at indicated time periods. The total number of leukocytes was counted as in Materials Methods. The results are expressed as mean SEM from three different mice for each point. At all time intervals, TNFu induced a significant leukocyte infiltration into the air pouch cavity *Statistically different from TNFa-treated cells; and from vehicle- or 15 R/S-methyl-LXA 4 -treated cells (p<0.01).
Figure 6 shows that 15 R/S-methyl-LXA 4 redirects the TNFa-induced cytokine/chemokine profile in vivo. Experiments were conducted as described in Figure legend. Quantitation for IL-13, IL-4, IL-10, IL-13 and MIP-2 was performed using ELISA with air pouch cell-free exudates. The results are expressed as mean SEM from three different mice for each point. Changes in IL-13, MIP-2 and IL-4 were significant at all tested time intervals (p<0.01).
DETAILED DESCRIPTION OF THE INVENTION The features and other details of the invention will now be more particularly described and pointed out in the claims. It will be understood that the particular embodiments of the invention are shown by way of illustration and not as limitations of the invention. The principle features of this invention can be employed in various embodiments without departing from the scope of the invention.
The impact of lipoxin A 4
(LXA
4 and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNFa)-initiated neutrophil (PMN) responses in vitro and in vivo using metabolically stable LX analogs. At concentrations as low as 1-10 nM, the LXA, and ATL analogs each inhibited TNFa-stimulated superoxide anion generation and IL-lp release by human PMN. These LXA 4 -ATL actions were time- and concentration-dependent and proved selective for TNFa, since these responses were not r altered with either GM-CSF or zymosan-stimulated cells. TNFa-induced IL-1 gene O expression was also regulated by both anti-LXA 4 -receptor antibodies and LXA.-ATL analogs. In murine air pouches, 15 R/S-methyl-LXA 4 dramatically inhibited TNFa- N stimulated leukocyte trafficking, as well as the appearance of both macrophage inflammatory peptide-2 and IL-1P, while concomitantly stimulating IL-4 in pouch 00 exudates. Together, these results indicate that both LXA 4 and ATL regulate TNFa directed neutrophil actions in vitro and in vivo and stimulate IL-4 in exudates, which plays a pivotal role in immune responses.
O Abbreviations used in this application: ATL, aspirin-triggered-lipoxin;
ATL
analog, 15R/S-methyl-LXA 4 -methyl ester; LX, lipoxin; LXA 4 5S, 6R, 7,9,13-trans- 11-cis-eicosatetraenoic acid; LXA 4 analog, 16 phenoxy-lipoxin
A
4 methyl ester; 15-epi-LXA 4 5S, 6R, .15R-trihydroxy-7,9,13-trans-11-cis-eicosatetraenoic acid; LT, leukotriene; MIP, macrophage inflammatory peptide; RA, rheumatoid arthritis. Suitable methods of preparation of lipoxin compounds can also be found, for example, in U.S.
Patent Nos. 5,411,951, 5,648,512, 5,650,435 and 5,750,354, incorporated herein by reference.
The contribution of leukotriene (LT')B 4 in inflammation is well established in view of its potent ability to attract PMN. Another series of bioactive lipid mediators termed lipoxins (LX) and aspirin-triggered lipoxins (ATL) each, within the nanomolar range, inhibits fMLP and LTB 4 stimulated PMN adhesion and transmigration and hence are proposed counter-regulatory signals operative in the resolution of inflammatory sites (Serhan, J.Z. Haeggstr6m, and C.C. Leslie. 1996. Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J. 10:1147-1158; Takano, S. Fiore, J.F. Maddox, H.R. Brady, N.A. Petasis, and C.N. Serhan. 1997. Aspirin-triggered lipoxin A 4 and LXA 4 stable analogs are potent inhibitors of acute inflammation: Evidence for anti-inflammatory receptors. J. Exp. Med. 185:1693-1704; Claria, and C.N. Serhan. 1995. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad. Sci. USA 92:9475-9479; Lee, C.E. Horton, U. Kyan-Aung, D. Haskard, A.E. Crea, and B.W. Spur. 1989.
Lipoxin A 4 and lipoxin B 4 inhibit chemotactic responses of human neutrophils stimulated by leukotriene B 4 and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. Clin.
0 Sci. 77:195-203; Serhan, C.N. 1994. Lipoxin biosynthesis and its impact in inflammatory Sand vascular events. Biochim. Biophys. Acta 1212:1-25). In human tissues, three main pathways are known for LX generation. An intraluminal source of LX is exemplified by N PMN-platelet interactions that utilize sequential transcellular biosynthetic routes with the PMN 5-lipoxygenase (LO) product LTA 4 and platelet 12-LO. The mucosal and/or interstitial source of these eicosanoids involves cell-cell interactions with leukocyte 00 and 15-LO present in, for example, eosinophils, gastrointestinal or tracheal epithelium that is controlled by IL-4 and IL-13 (reviewed in (Serhan, J.Z. Haeggstram, and C.C. Leslie. 1996. Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J. 10:1147-1158)). The third and most recently elucidated also represents a novel mechanism of action for aspirin that triggers the endogenous biosynthesis of 15 R epimers of native LX, termed aspirin-triggered lipoxins (ATL), generated via transcellular biosynthesis (ClAria, and C.N. Serhan. 1995. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cellleukocyte interactions. Proc. Nail. Acad. Sci. USA 92:9475-9479).
LX are generated during cell-cell interactions via transcellular biosynthesis, and are produced in vivo during angioplasty and in immune complex glomerulonephritis (Serhan, J.Z. Haeggstr6m, and C.C. Leslie. 1996. Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J. 10:1147-1158; Papayianni,
C.N.
Serhan, M.L. Phillips, H.G. Rennke, and H.R. Brady. 1995. Transcellular biosynthesis of lipoxin A 4 during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis. Kidney Int. 47:1295-1302).
LXA
4 is also present in nasal lavage fluids of aspirin-sensitive asthmatics and is generated by leukocytes from patients with asthma and rheumatoid arthritis (Chavis, I. Vachier, P. Chanez, J. Bousquet, and P.
Godard. 1996. 5(S),15(S)-Dihydroxyeicosatetraenoic acid and lipoxin generation in human polymorphonuclear cells: dual specificity of 5-lipoxygenase towards endogenous and exogenous precursors. J Exp. Med. 183:1633-1643; Thomas, J.L. Leroux, F.
Blotman, and C. Chavis. 1995. Conversion of endogenous arachidonic acid to 5,15diHETE and lipoxins by polymorphonuclear cells from patients with rheumatoid arthritis.
Inflamm. Res. 44:121-124). Like most autacoids and lipid mediators, LX are rapidly biosynthesized, act within a local microenvironment, and are rapidly enzymatically inactived. To advance the understanding of LX and ATL roles in vivo, metabolically 0 stable LX analogs were designed that resist rapid inactivation and mimic the in vitro I actions of naturally occurring LX and ATL (Serhan, J.F. Maddox, N.A. Petasis, 1.
S Akritopoulou-Zanze, A. Papayianni, H.R. Brady, S.P. Colgan, and J.L. Madara. 1995.
O
Design of lipoxin A 4 stable analogs that block transmigration and adhesion of human CI neutrophils. Biochemistry 34:14609-14615). It has been unexpectedly discovered that these compounds are potent inhibitors of TNFu-driven PMN-associated inflammatory 0 events in vitro as well as in vivo. Moreover, LXA 4 -ATL inhibit MIP-2 and IL-1 P yet i stimulate the local appearance of IL-4 within exudates.
The present invention pertains to methods for modulating a disease or condition Sassociated with TNFa initiated polymorphoneutrophil (PMN) inflammation. The methods include administration to a subject, an effective anti-inflammatory amount of a lipoxin analog having the formula described infra, such that the TNFa initated PMN inflammation is modulated.
The present invention also pertains to methods for treating TNFa initiated polymorphoneutrophil (PMN) inflammation in a subject. The methods include administration of an effective anti-inflammatory amount of a lipoxin analog described infra, such that TNFa initiated polymorphoneutrophil (PMN) inflammation is treated.
The present invention further pertains to methods for modulating a disease or condition associated with TNFa initiated cytokine activity in a subject. The methods include, administration of an effective anti-TNFa amount of a lipoxin analog described infra, such that a disease or condition associated with TNFa initiated cytokine activity, is modulated.
The present invention further relates to methods for treating TNFa initiated cytokine activity in a subject. The methods include administration of an effective antiinflammatory amount of a lipoxin analog described itnfra, such that TNFa initiated cytokine activity, inflammation, is treated.
The present invention also relates to methods for modulating a disease or condition associated with TNFct initiated IL-11 activity in a subject. The methods include administration of an effective anti-TNFa amount of a lipoxin analog described intfra, such that a disease or condition associated with TNFca initiated IL-lp, is modulated.
The present invention further pertains to methods for treating TNFa initiated IL- 1 p activity in a subject. The methods include administration of an effective anti-TNFa amount of a lipoxin analog described infra, such that TNFa initiated IL-1 activity, inflammation, is treated.
00 In preferred embodiments, the methods of the invention are performed in vitro or in vivo.
tn In another aspect, the present invention is directed to a packaged pharmaceutical 00 composition for treating a the activity or conditions listed above in a subject. The packaged pharmaceutical composition includes a container holding a therapeutically 1effective amount of at least one lipoxin compound having one of the formulae described infra and instructions for using the lipoxin compound for treating the activity or condition in the subject.
In one embodiment, compounds useful in the invention have the formula (I) 1 Q4,H Q3H R2
QX
x R4 R3 2 R6 YJ wherein X is R 1 OR,, or SR,; wherein R, is a hydrogen atom; (ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched; (iii) a cycloalkyl of 3 to 10 carbon atoms; (iv) an aralkyl of 7 to 12 carbon atoms; phenyl; (vi) substituted phenyl SZi Zii O -1 Ziii V) z z iv l 00 oo ,i wherein and Z, are each independently selected from -NO, S-CN,
-SO
3 H, a hydrogen atom, halogen, methyl, -ORx, wherein 0 O R is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl; (vii) a detectable label molecule; or (viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive; wherein Q, is SO 2 or provided when Q, is CN, then X is absent; wherein Q 3 and Q 4 are each independently O, S or NH; wherein one of R, and R 3 is a hydrogen atom and the other is
H;
an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched; a cycloalkyl of 3 to 6 carbon atoms, inclusive; an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or
R.Q
2 Rb wherein Q2 is or wherein R, is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein Rb is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when Rb is 0, then R, is a hydrogen atom; wherein R 4 is
H;
an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched; wherein R 5 is Zi Zii Zii Z" Zi wherein and Z, are each independently selected from -NO 2 -CN,
-SO
3 H, a hydrogen atom, halogen, methyl, wherein Rx is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group; wherein Y, is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CHZb where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen; wherein R 6 is
H;
an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched; wherein T is O or S, and pharmaceutically acceptable salts thereof.
In another embodiment, compounds useful in the invention have the formula (II) HO OH R2 O 00 C I R4 5 R 3
T
00 SR6 YJ Swherein X is OR,, or SR,; wherein R, is a hydrogen atom; (ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched; (iii) a cycloalkyl of 3 to 10 carbon atoms; (iv) an aralkyl of 7 to 12 carbon atoms; phenyl; (vi) substituted phenyl Zi Zii -iii wherein and are each independently selected from -NO 2 O -CN, -SO 3 H, a hydrogen atom, halogen, methyl, wherein R, is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl; (vii) a detectable label molecule; or CN, (viii) a straight or branched chain alkenyl of 2 to 8 carbon O atoms, inclusive;
O
wherein Q, is SO, or provided when Q, is CN, then X is absent; in wherein one of R, and R 3 is a hydrogen atom and the other is 00 OO S(a) H; S(b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a Ostraight chain or branched; a cycloalkyl of 3 to 6 carbon atoms, inclusive; an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or
RQ
2 Rb wherein Q 2 is or wherein Ra is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein Rb is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when Rb is 0, then Rb is a hydrogen atom; wherein R 4 is
H;
an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched; wherein R 5 is wherein and Z, are each independently selected from -NO,.
-CN, -SO 3 H, a hydrogen atom, halogen, methyl, wherein R, is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched.
and hydroxyl or a substituted or unsubstiruted, branched or unbranched alkyl group; wherein Y, is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH,Zb where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen; wherein R. is
H;
an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched; wherein T is O or S, and pharmaceutically acceptable salts thereof.
The invention is also directed to useful lipoxin compounds having the formula
(III)
X
R
5
R
3
T
wherein X is OR,, or SR,; wherein R, is -13- S(i) a hydrogen atom: c (ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may o be straight chain or branched; CNK (iii) a cycloalkyl of 3 to 10 carbon atoms; (iv) an aralkyl of 7 to 12 carbon atoms; tI phenyl; oO (vi) substituted phenyl Zi Zii -t Ziii Z, Ziv wherein Zi, Ziji, and Z, are each independently selected from -NO,, -CN,
-SO
3 H, a hydrogen atom, halogen, methyl, wherein Rx is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl; (vii) a detectable label molecule; or (viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive; wherein Q, is SO, or provided when Q, is CN, then X is absent; wherein one of R 2 and R 3 is a hydrogen atom and the other is
H;
an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched; a cycloalkyl of 3 to 6 carbon atoms, inclusive; S(d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be cN straight chain or branched; or O
RQ
2 R, wherein Q 2 is or wherein R, is alkylene of 0 to
O
6 carbons atoms, inclusive, which may be straight chain or c branched and wherein R, is alkyl of 0 to 8 carbon atoms, inclusive, 0. which may be straight chain or branched, provided when R, is 0, then Rb is a hydrogen atom; 0 wherein R 4 is
H;
an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched; wherein R 5 is Zi Zii Ziii zv Ziv wherein Z, and Z, are each independently selected from -NO, -CN,
-SO
3 H, a hydrogen atom, halogen, methyl, wherein Rx is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group; wherein R, is
O
H;
an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched; wherein T is O or S, and pharmaceutically acceptable salts thereof.
The invention is further directed to useful lipoxin compounds having the formula (TV) HO OH Q1 I x
T/R
R
6
OH
wherein X is OR,, or SR,; wherein R, is (i) (ii) (iii) (iv) (v) (vi) substiru ted phenyl a hydrogen atom; an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched; a cycloalkyl of 3 to 10 carbon atoms; an aralkyl of 7 to 12 carbon atoms; phenyl; Zi Zii Zii wherein Z i Zi, and Z, are each independently selected from -NO,, -CN,
-SO
3 H, a hydrogen atom, halogen, methyl, wherein R, is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched,and hydroxyl; (vii) (viii) a detectable label molecule; or a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive; wherein Q, is SO 2 or provided when Q, is CN, then X is absent; wherein R 4 is
H;
an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched; wherein R 5 is wherein and Z, are each independently selected from -NO 2 -CN, -SOH, a hydrogen atom, halogen, methyl, wherein R, is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, -17and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group; wherein R 6 is
H;
an alkyl from 1 to 4 carbon atoms,. inclusive, straight chain or..
branched; wherein T is O or S, and pharmaceutically acceptable salts thereof.
The invention is further directed to useful lipoxin compounds having the formula (V) wherein X is R 1 OR,, or SRi; wherein R, is a hydrogen atom; (ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched; (iii) a cycloalkyl of 3 to 10 carbon atoms; (iv) an aralkyl of 7 to 12 carbon atoms; phenyl; (vi) substituted phenyl SZi ZiI Z, z,, Zv Ziv oo wherein Zi, Zii, Ziii, Ziv and Zv are each independently selected from -NO 2 cN 5 CN, 1
-SO
3 H, a hydrogen atom, halogen, methyl, -ORx, wherein Rx is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and
O
0 hydroxyl; (vii) a detectable label molecule; or (viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive; wherein Q 1 is SO 2 or provided when Q1 is CN, then X is absent; wherein R 4 is
H;
an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched; wherein R 5 is z\ /-Zi Zv Zv wherein Zi, and Z, are each independently selected from -NO 2
O
S-CN, -S03H, a hydrogen atom, halogen, methyl, wherein
R
1 is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, O and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl CI group; C wherein R6 is 00
H;
an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched; and pharmaceutically acceptable salts thereof.
In preferred embodiments, X is OR, wherein R, is a hydrogen atom, an alkyl group of 1 to 4 carbon atoms or a pharmaceutically acceptable salt, Q 1 is C=O, R 2 and
R
3 if present, are hydrogen atoms, R 4 isa hydrogen atom or methyl, Q 3 and Q 4 if present, are both O, R, if present, is a hydrogen atom, if present, is OH, T is O and R, is a substituted phenyl, e.g., 2z Zii Ziii Zi, wherein Z,i, and Z, are each independently selected from -NO 2 -CN, -SO 3 H, a hydrogen atom, halogen, methyl, -OR, wherein R is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl.
In certain embodiments for para-fluorophenyl and unsubstituted phenyl are excluded, 15-epi-16-(para-fluoro)-phenoxy-LXA 4 15-epi-16-phenyoxy-LXA 4 16- O (para-fluoro)-phenoxyl-LXA 4 and/or 16-phenoxy-LXA 4 The compounds
C
encompassed by U.S. Patent 5,441,951 are excluded from certain aspects of the t present invention.
In preferred embodiments, Y 1 is a hydroxyl and the carbon bearing the 00 5 hydroxyl can have an R or S configuration. In most preferred embodiments, the chiral carbon bearing the hydroxyl group, Y 1 is designated as a lipoxin as is known in the art.
oO 00 In certain embodiments the chirality of the carbons bearing the R 2
R
3 Q3 and Q4 groups can each independently be either R or S. In preferred embodiments, Q3 and Q4 have the chiralities shown in structures II, III, IV or V.
N In preferred embodiments, R4 is a hydrogen. In other preferred embodiments, R 6 is a hydrogen.
Additionally, R 5 can be a substituted or unsubstituted, branched or unbranched alkyl group having between 1 and about 6 carbon atoms, preferably between 1 and 4 carbon atoms, most preferably between 1 and 3, and preferably one or two carbon atoms. The carbon atoms can have substituents which include halogen atoms, hydroxyl groups, or ether groups.
In a preferred embodiment of the invention there is provided a method for modulating seborrheic dermatitis, pustular dermatosis or dandruff associated with TNFa initiated polymorphoneutrophil (PMN) inflammation in a subject, comprising administering to the subject an effective anti-TNFu amount of a lipoxin analog having the formula: wherein X is R 1
OR
1 or SR 1 21a r- O wherein R 1 is N a hydrogen atom; (ii) an alkyl of 1 to 8 carbon atoms, inclusive, which may be straight chain or branched; 00 0 5 (iii) a cycloalkyl of 3 to 10 carbon atoms; (iv) an aralkyl of 7 to 12 carbon atoms; phenyl; 00 (vi) substituted phenyl (N Z, ZiI wherein Zi, Zi, Zii, Ziv and Zv are each independently selected from -NO 2 -CN, -SO 3 H, a hydrogen atom, halogen, methyl, -ORx, wherein Rx is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl; (vii) a detectable label molecule; or (viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive; wherein RT is a hydrogen atom; (ii) an alkyl of 1 to 8 carbon atoms, inclusive, which may be straight chain or branched; (iii) a cycloalkyl of 3 to 10 carbon atoms; (iv) an aralkyl of 7 to 12 carbon atoms; phenyl; (vi) substituted phenyl 21b 0
Z
i /Zii Zii i SZ Zi, In 00 wherein Zi, Zi, Ziii, Ziv and Zv are each independently selected from -NO 2 9 -CN, -SO 3 H, a hydrogen atom, halogen, methyl, -ORx, wherein Rx is 1 to 8 carbon 5 atoms, inclusive, which may be a straight chain or branched, and hydroxyl; 0(vii) a detectable label molecule; or (viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive; wherein Q 1 is SO 2 or provided when Q 1 is CN, then X is absent; wherein Q3 and Q4 are each independently O, S or NH; wherein one of R 2 and R 3 is a hydrogen atom and the other is
H;
an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched; a cycloalkyl of 3 to 6 carbon atoms, inclusive; an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or RaQ2Rb wherein Q2 is or wherein Ra is alkylene of 0 to 6 carbon atoms, inclusive, which may be straight chain or branched and wherein Rb is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when Rb is 0, then Rb is a hydrogen atom; wherein R 4 is
H;
an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched; wherein R 5 is 21c 0 zii Z' Zi In 00 wherein Zi, Zii, Ziii, Ziv and Zv are each independently selected from -NO 2 -CN, -SO 3 H, a hydrogen atom, halogen, methyl, -ORx, wherein Rx is 1 5 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and 0 hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group; wherein Y 1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CHaZb where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen; wherein R 6 is
H;
an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched; wherein T is O or S, and pharmaceutically acceptable salts thereof, such that seborrheic dermatitis, pustular dermatosis or dandruff associated with TNFao initiated polymorphoneutrophil (PMN) inflammation is modulated in a subject.
The compounds useful in the present invention can be prepared by the following synthetic scheme: HQ4 Q3H R2 o CN R4 "C Me 3 Si R3 In o 0 catalytic hydrogenation
R
C Br
T
HQ4 Q3H R2 'RT R5 R3
T
R
6 Y1 wherein X, Q 3
Q
4
R
2
R
3
R
4 R, R 6 YI and T are as defined above. Suitable methods known in the art to can be used to produce each fragment. For example, the acetylenic fragment can be prepared by the methods discussed in Nicolaou, K.C. et al.
(1991) Angew. Chem. Int. Ed. Engl. 30:1100; Nicolaou, K.C. et al. (1989) J. Org. Chem.
54:5527; Webber, S.E. et al. (1988) Adv. Exp. Med. Biol. 229:61; and U.S. Patent 5,441,951. The second fragment can be prepared by the methods of Raduchel, B. and Vorbruggen, H. (1985) Adv. Prostaglandin Thromboxane Leukotriene Res. 14:263.
In still another aspect, the present invention is directed to pharmaceutical compositions including compounds having the above-described formulae and a pharmaceutically acceptable carrier. In one embodiment, a preferred compound is -22c
OH
00 In a preferred embodiment, the pharmaceutical carrier is not a ketone, acetone.
O
In one embodiment, the antiinflammatories of the invention can be incorporated into a shampoo or a body cleansing product, a soap, for cleansing of the scalp and/or body. The use of these compounds in a shampoo or soap product can be used to treat psoriasis, seborrheic dermatitis, pustular dermatosis and dandruff. Thus the compounds are useful for modulating TNF aPMN or cytokine inflammation associated with such conditions.
A "lipoxin analog" shall mean a compound which has an "active region" that functions like the active region of a "natural lipoxin", but which has a "metabolic transformation region" that differs from natural lipoxin. Lipoxin analogs include compounds which are structurally similar to a natural lipoxin, compounds which share the same receptor recognition site, compounds which share the same or similar lipoxin metabolic transformation region as lipoxin, and compounds which are art-recognized as being analogs of lipoxin. Lipoxin analogs include lipoxin analog metabolites. The compounds disclosed herein may contain one or more centers of asymmetry. Where asymmetric carbon atoms are present, more than one stereoisomer is possible, and all possible isomeric forms are intended to be included within the structural representations shown. Optically active and isomers may be resolved using conventional techniques known to the ordinarily skilled artisan. The present invention is intended to include the possible diastereiomers as well as the racemic and optically resolved isomers.
-23- SThe terms "corresponding lipoxin" and "natural lipoxin" refer to a naturallyoccurring lipoxin or lipoxin metabolite. Where an analog has activity for a lipoxin- O specific receptor, the corresponding or natural lipoxin is the normal ligand for that CI receptor. For example, where an analog is a LXA 4 specific receptor on differentiated cells, the corresponding lipoxin is LXA 4 Where an analog has activity as an I antagonist to another compound (such as a leukotriene), which is antagonized by a 00 naturally-occurring lipoxin, that natural lipoxin is the corresponding lipoxin.
C-I "Active region" shall mean the region of a natural lipoxin or lipoxin analog, 1 which is associated with in vivo cellular interactions. The active region may bind the "recognition site" of a cellular lipoxin receptor or a macromolecule or complex of macromolecules, including an enzyme and its cofactor. Preferred lipoxin A 4 analogs have an active region comprising C 5 of natural lipoxin A 4 Preferred lipoxin B 4 analogs have an active region comprising C5-C14 of natural lipoxin B4.
The term "recognition site" or receptor is art-recognized and is intended to refer generally to a functional macromolecule or complex of macromolecules with which certain groups of cellular messengers, such as hormones, leukotrienes, and lipoxins, must first interact before the biochemical and physiological responses to those messengers are initiated. As used in this application, a receptor may be isolated, on an intact or permeabilized cell, or in tissue, including an organ. A receptor may be from or in a living subject, or it may be cloned. A receptor may normally exist or it may be induced by a.disease state, by an injury, or by artificial means. A compound of this invention may bind reversibly, irreversibly, competitively, noncompetitively, or uncompetitively with respect to the natural substrate of a recognition site.
The term "metabolic transformation region" is intended to refer generally to that portion of a lipoxin, a lipoxin metabolite, or lipoxin analog including a lipoxin analog metabolite, upon which an enzyme or an enzyme and its cofactor attempts to perform one or more metabolic transformations which that enzyme or enzyme and cofactor normally transform on lipoxins. The metabolic transformation region may or may not be susceptible to the transformation. A nonlimiting example of a metabolic transformation region of a lipoxin is a portion of LXA 4 that includes the C-13,14 double bond or the C-15 hydroxyl group, or both.
-24- O The term "detectable label molecule" is meant to include fluorescent, phosphorescent, and radiolabeled molecules used to trace, track, or identify the O compound or receptor recognition site to which the detectable label molecule is bound.
CI The label molecule may be detected by any of the several methods known in the art.
The term "labeled lipoxin analog" is further understood to encompass compounds which are labeled with radioactive isotopes, such as but not limited to o0 tritium 3 deuterium carbon 4 or otherwise labeled fluorescently).
i The compounds of this invention may be labeled or derivatized, for example, for kinetic binding experiments, for further elucidating metabolic pathways and enzymatic Omechanisms, or for characterization by methods known in the art of analytical chemistry.
The term "inhibits metabolism" means the blocking or reduction of activity of an enzyme which metabolizes a native lipoxin. The blockage or reduction may occur by covalent bonding, by irreversible binding, by reversible binding which has a practical effect of irreversible binding, or by any other means which prevents the enzyme from operating in its usual manner on another lipoxin analog, including a lipoxin analog metabolite, a lipoxin, or a lipoxin metabolite.
The term "resists metabolism" is meant to include failing to undergo one or more of the metabolic degradative transformations by at least one of the enzymes which metabolize lipoxins. Two nonlimiting examples of LXA, analog that resists metabolism are 1) a structure which can not be oxidized to the 15-oxo form, and 2) a structure which may be oxidized to the 15-oxo form, but is not susceptible to enzymatic reduction to the 13,14-dihydro form.
The term "more slowly undergoes metabolism" means having slower reaction kinetics, or requiring more time for the completion of the series of metabolic transformations by one or more of the enzymes which metabolize lipoxin. A nonlimiting example of a LXA, analog which more slowly undergoes metabolism is a structure which has a higher transition state energy for C-15 dehydrogenation than does
LXA
4 because the analog is sterically hindered at the C-16.
The term "tissue" is intended to include intact cells, blood, blood preparations such as plasma and serum, bones, joints, muscles, smooth muscles, and organs.
The term "halogen" is meant to include fluorine, chlorine, bromine and iodine, c or fluoro, chloro, bromo, and iodo. In certain aspects, the compounds of the invention O do not include halogenated compounds, fluorinated compounds.
O
The term "subject" is intended to include living organisms susceptible to
C
conditions or diseases caused or contributed to by inflammation, inflammatory In responses, vasoconstriction, and myeloid suppression. Examples of subjects include N humans, dogs, cats, cows, goats, and mice. The term subject is further intended to include transgenic species.
When the compounds of the present invention are administered as Spharmaceuticals, to humans and mammals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.
The phrase "pharmaceutically acceptable carrier" as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a compound(s) of the present invention within or to the subject such that it can perform its intended function. Typically, such compounds are carried or transported from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations.
-26- O In certain embodiment, the compounds of the present invention may contain one SN or more acidic functional groups and, thus, are capable of forming pharmaceutically Sacceptable salts with pharmaceutically acceptable bases. The term "pharmaceutically
O
C acceptable salts" in these instances refers to the relatively non-toxic, inorganic and organic base addition salts of compounds of the present invention. These salts can likewise be prepared in situ during the final isolation and purification of the compounds, OO or by separately reacting the purified compound in its free acid form with a suitable base, S such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary 0 or tertiary amine. Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like.
Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like.
The term "pharmaceutically acceptable esters" refers to the relatively non-toxic, esterified products of the compounds of the present invention. These esters can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a suitable esterifying agent. Carboxylic acids can be converted into esters via treatment with an alcohol in the presence of a catalyst. The term is further intended to include lower hydrocarbon groups capable of being solvated under physiological conditions, alkyl esters, methyl, ethyl and propyl esters. In a preferred embodiment, the ester is not a methyl ester (See, for example, Berge et al., supra.).
Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
Examples of pharmaceutically acceptable antioxidants include: water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and metal chelating agents, such as citric -27- O acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, iartaric acid, phosphoric acid, N and the like.
O Formulations of the present invention include those suitable for intravenous, oral, N nasal, topical, transdermal, buccal, sublingual, rectal, vaginal and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and to may be prepared by any methods well known in the art of pharmacy. The amount of 0 active ingredient which can be combined with a carrier material to produce a single N dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 per cent to about 70 per cent, most preferably from about 10 per cent to about 30 per cent.
Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient. A compound of the present invention may also be administered as a bolus, electuary or paste.
In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, -28- 0 potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; solution C N retarding agents, such as paraffin; absorption accelerators, such as quaternary ammonium compounds; wetting agents, such as, for example, cetyl alcohol and glycerol N monostearate; absorbents, such as kaolin and bentonite clay; lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, It and mixtures thereof; and coloring agents. In the case of capsules, tablets and pills, the 00 pharmaceutical compositions may also comprise buffering agents. Solid compositions of N1 a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight i polyethylene glycols and the like.
A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active O ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the N above-described excipients.
C.)
o Liquid dosage forms for oral administration of the compounds of the invention S include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may I contain inert diluents commonly used in the art, such as, for example, water or other 0 solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and 0 sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitanesters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a 0 pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants C which may be required.
o The ointments, pastes, creams and gels may contain, in addition to an active
O
C, compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, S paraffins, starch, tragacanth, cellulose derivatives, polyethylefie glycols; silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
OO Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain Scustomary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active compound in a polymer matrix or gel.
Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this invention.
Pharmaceutical compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, 0 such as lecithin, by the maintenance of the required particle size in the case of N dispersions, and by the use of surfactants.
O These compositions may also contain adjuvants such as preservatives, wetting
O
C agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also oo be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as 0 aluminum monostearate and gelatin.
In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form.
Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide.
Depending on the ratio of drug to polymer, and the natureof the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.
The preparations of the present invention may be given orally, parenterally, topically, or rectally. They are of course given by forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Intravenous injection administration is preferred.
The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, -32usually by injection, and includes, without limitation, intravenous, intramuscular, 1 intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, O intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, O subarachnoid, intraspinal and intrastemal injection and infusion.
CN The phrases "systemic administration," "administered systematically," "peripheral administration" and "administered peripherally" as used herein mean the administration I of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like 4 processes, for example, subcutaneous administration.
SThese compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually.
Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of ordinary skill in the art.
Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required W in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
In general, a suitable daily dose of a compound of the invention will be that O amount of the compound which is the lowest dose effective to produce a therapeutic N effect. Such an effective dose will generally depend upon the factors described above; Generally, intravenous and subcutaneous doses of the compounds of this invention for a In CN patient, when used for the indicated analgesic effects, will range from about 0.0001 to 00 C about 100 mg per kilogram of body weight per day, more preferably from about 0.01 to N about 50 mg per kg per day, and still more preferably from about 0.1 to about 40 mg per Skg per day. For example, between about 0.01 microgram and 20 micrograms, between about 20 micrograms and 100 micrograms and between about 10 micrograms and 200 micrograms of the compounds of the invention are administered per 20 grams of subject weight.
If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
While it is possible for a compound of the present invention to be administered alone, it is preferable to administer the compound as a pharmaceutical composition.
Materials and Methods Human and mouse recombinant TNFa and human recombinant GM-CSF were obtained from Boehringer Mannheim (Indianapolis, IN). Dulbecco's PBS (Mg" and Ca"-free), RPMI-1640 and FCS were purchased from Bio Whittaker Inc.
(Walkersville, MD). Ficoll-Hypaque was from Organon Teknika Corp. (Durham, NC) and Hank's balanced salt solution was purchased from Gibco BRL (Grand Island, NY).
Serum bovine albumin, dextran, antibiotics, L-glutamine, cytochrome C, superoxide dismutase and zymosan were obtained from Sigma (St. Louis, MO). The assessment of human IL-lp in supernatants was performed by using an immunometric assay with acetylcholine esterase (Cayman Chemical, Ann Arbor, MI). Murine IL-13 was assessed using an ELISA from Endogen (Woburn, MA). ELISAs for IL-4 and were from Amersham (Arlington Heights, IL); MIP-2 and IL-13 ELISAs were from R&D Systems (Minneapolis, MN). LXA 4 and ATL metabolically stable analogs were -34- 0 prepared and characterized, including nuclear magnetic resonance spectroscopy, as in I Concentrations of each LX analog were determined using an extinction S coefficient of 50,000 M-'.cm-'just prior to each experiment. Where indicated, statistical analyses were performed using Student's non-paired t-test (two-tailed), and significance was considered to be attained when P was 0.05.
0 Preparation of human PMN suspensions and superoxide-anion generation Venous blood from healthy donors was collected using sterile conditions using Sacid citrate dextrose (ACD) as an anticoagulant, and PMN were isolated as in O PMN were suspended in cold (4 0 C) Hank's medium (supplemented with 1.6 mM Ca", 0.1% FCS, 2 mM L-glutamine, 1% penicillin, and 2% streptomycin, pH 7.4).
Cell preparations were 98% PMN as determined by Giemsa-Wright staining; cell viability was 98% as determined by trypan blue exclusion and light microscopy. To examine superoxide production, PMN (1.0 x 10 6 /ml) were placed at 37 0 C (3 min) and then exposed to either vehicle ethanol) or synthetic LXA 4 15R/S-methyl LXA 4 or 16-phenoxy-LXA 4 for 5 min at 37 0 C. Before adding TNFa (50 ng/ml), PMN were incubated with cytochrome C (0.7 mg/ml) for 10 min at 37 o C. Superoxide dismutasedependent reduction of cytochrome C was terminated by rapidly placing tubes in an icewater bath. The extent of cytochrome C reduction in each supernatant was determined at 550 nm in reference to control values obtained when superoxide dismutase was added before a stimulus or vehicle control. Cytochrome C reduction was quantitated using the extinction coefficient of 21.1/mmol/L.
RNA isolation and Northern blot analysis Total RNA extraction and Northern blot analyses were performed as in pSM320 vector containing cDNA for IL-13 was purchased from ATCC.
Murine air pouches Six to eight week old male BALB/c mice were obtained from Taconic Farms (Germantown, NY). Air pouches were raised on the dorsum by s.c. injection of 3 ml of sterile air on day 0 and day 3. All experiments were conducted on day 6 (16).
Individual air pouches (one per mouse) were injected with either vehicle alone (0.1% 0 ethanol), TNFa, 15 R/S-methyl-LXA 4 or TNFa plus 15 R/S-methyl-LXA 4 and each I was suspended in 1 ml endotoxin-free PBS immediately before injection into pouch O cavities. At given intervals, the mice were sacrificed and individual air pouches were
O
S lavaged three times with sterile PBS (1 ml). The exudates were centrifuged at 2000 RPM (5 min) and the supernatants were removed. Cell pellets were suspended in PBS (200 pl) for enumeration and assessed for viability. Fifty yl of each cell suspension 0 was mixed with 150 tl 30% BSA and then centrifuged onto microscope slides at 500 -I RPM for 5 min using a cytospin centrifuge, air dried, and stained with Giemsa-Wright.
0 Inhibition of TNFa-stimulated superoxide generation TNFat, although a modest agonist ofO,- generation by human PMN, is a physiologically relevant stimulus for the generation of reactive oxygen species (ROS) by human PMN that can play critical roles in local tissue injury during both inflammation and reperfusion (Tsujii, S. Kawano, S. Tsuji, H. Sawaoka, M. Hori, and R.N. DuBois.
1998. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705- 716; Shibuya, N. Ohkohchi, S. Tsukamoto, and S. Satomi. 1997. Tumor necrosis factor-induced, superoxide-mediated neutrophil accumulation in cold ischemic/reperfused rat liver. Hepatology 26:113-120; Jaeschke, A. Farhood, and C.W. Smith. 1990.
Neutrophils contribute to ischemia/reperfusion injury in rat liver in vivo. FASEB J.
4:3355-3359). In Figure 1, the impact of LXA 4 and ATL related bioactive stable analogs were evaluated on TNFa stimulated superoxide anion production. Native LXA 4 and the analogs (15 R/S-methyl-LXA 4 and 16 phenoxy-LXA 4 inhibited TNFa-stimulated superoxide anion generation in a concentration-dependent fashion. Their rank order of potency at 10 nM was 15 R/S-methyl-LXA 4 (81.3 14.1% inhibition) 16 phenoxy-
LXA
4 (93.7 LXA 4 (34.3 15R/S-methyl-LXA 4 covers both LXA and ATL in structure, and 16-phenoxy-LXA 4 is a LXA 4 analog (see Fig. Each analog competes at the LXA 4 receptor. (Takano, S. Fiore, J.F. Maddox, H.R. Brady, N.A.
Petasis, and C.N. Serhan. 1997. Aspirin-triggered 15-epi-lipoxin A 4 and LXA 4 stable analogs are potent inhibitors of acute inflammation: Evidence for anti-inflammatory receptors. J. Exp. Med. 185:1693-1704.) Neither LXA 4 15 R/S-methyl-LXA 4 nor 16 phenoxy-LXA 4 at concentrations up to 1000 nM added to cells alone, stimulated generation of ROS. 15 R/S-methyl-LXA 4 and 16 phenoxy-LXA 4 were approximately -36- O three times more potent than native LXA 4 and proved to be powerful inhibitors of TNFastimulated superoxide generation by PMN. However, neither LXA 4 nor its analogs o inhibit PMA (100 nM; n=3; not shown) or fMLP-stimulated Oz, production. Inhibition of ROS by LXA 4 and its analogs is of interest in a context of ischemia/reperfusion, where ROS are held to be primary mediators of tissue injury OO Suppression of TNFa-stimulated IL-10 release PMN express and release interleukin-1 P, which is a potent proinflammatory cytokine (Dinarello, C.A. 1996. Biologic basis for interleukin-1 in disease. Blood 87:2095-2147). Therefore, the actions of native LXA 4 and its analogs on TNFa-induced IL-1 P release were investigated. Incubation of PMN with physiologically relevant concentrations of TNFa, GM-CSF or phagocytic particles (zymosan) resulted in a concentration dependent increase in the levels of IL-1 P present in supernatants.
Approximate
EC
5 0 for each agonist were: TNFa, 10 ng/ml; GM-CSF, 10 U/ml; and zymosan, 100 /zg/ml. Native LXA 4 specifically inhibited TNFu-induced IL-10 release (Fig. 2A), while similai amounts of IL- lp were released in the presence or absence of
LXA
4 when PMN were exposed to either GM-CSF or zymosan.
PMN were exposed to increasing concentrations of 15 R/S-methyl-LXA 4 16phenoxy-LXA 4 or native LXA 4 in the presence of TNFa (10 ng/ml) or vehicle alone. At a concentration of 100 nM, 15 R/S-methyl-LXA 4 inhibited 60 ofIL-10 release, and 16-phenoxy-LXA 4 at equimolar levels gave approximately 40% inhibition (values comparable to those obtained with native LXA 4 Time course and concentration dependence were carried out with 15 R/S-methyl
LXA
4 (Fig 2B). At 10 nM, 15 R/Smethyl-LXA 4 gave clear statistically significant inhibition, which was evident within 6 h and more prominent after 24 h (Fig. 2B). Inhibition of IL-11 by these LX analogs was, at least in part, the result of a down-regulation in gene expression, since the IL-1 3 messenger RNA levels in cells treated with TNFo (10 ng/ml) plus 15 R/S-methyl-LXA 4 (100 nM) were decreased by approximately 60 when compared to cells treated with TNFc alone (Fig. Therefore, since IL-1 P and TNFu are two cytokines that are considered important in inflammation, the inhibition of IL-11P observed (Figs. 1 2 suggested that 15 R/S-methyl-LXA 4 might exert a potent in vivo anti-cytokine action (vide infra).
0 Involvement of LXA 4 receptor To investigate whether the LXA 4 receptor (LXA 4 was involved in the o regulation of TNFa-stimulated IL- P1 release, the rabbit polyclonal antibodies against a S portion of the third extracellular domain (ASWGGTPEERLK) of LXA 4 -R prepared earlier were used (Fiore, and C.N. Serhan. 1995. Lipoxin A 4 receptor activation is distinct from that of the formyl peptide receptor in myeloid cells: inhibition of CD11/18 00 expression by lipoxin A 4 -lipoxin A4 receptor interaction. Biochemistry 34:16678-16686).
N PMN were incubated with- 50 ,g/ml of either preimmune protein-A purified IgG or IgG Sdirected against LXA 4 -R for 1 h at 4 °C prior to exposure to TNFc (10 ng/ml) and R/S-methyl-LXA 4 (100 nM). Anti-LXA4-R antibodies prevented IL-1 release by TNFa, suggesting that the third extracellular loop plays a crucial role in LXA 4 receptor activation (Fig. 15 R/S-methyl-LXA 4 inhibited about 50 of IL-13 release. When added together, anti-LXA 4 -R antibodies and 15R/S-methyl-LXA 4 in the presence of TNFa did not further inhibit IL- 1 appearance, and neither anti-LXA 4 -R antibodies nor 15 R/S-LXA 4 alone stimulated significant amounts of IL-1p to appear within supematants. The results of these experiments are two fold: first, they indicated that the inhibitory action of 15 R/S-methyl-LXA 4 is transduced via the LXA 4 receptor and second, that the anti-LXA 4 -R antibodies alone activate the LXA 4 receptor and lead to inhibition of IL-1 P release.
Inhibition of TNFa-directed leukocyte trafficking in vivo Since TNFa evokes leukocyte infiltration in a chemokine-dependent fashion in the murine six day air pouch, the impact of 15 R/S-methyl-LXA4 in this model was evaluated to determine whether LXA 4 or ATL also intersects the cytokine-chemokine axis in vivo (Tessier, P.H. Naccache, I. Clark-Lewis, R.P. Gladue, K.S. Neote, and S.R. McColl. 1997. Chemokine networks in vivo: involvement of C-X-C and C-C chemokines in neutrophil extravasation in vivo in response to TNF-a. J. Immunol.
159:3595-3602; Sin, A.D. Sedgwick, E.P. Chea, and D.A. Willoughby. 1986. Mast cells in newly formed lining tissue during acute inflammation: a six day air pouch model in the mouse. Ann. Rheum. Dis. 45:873-877). 15 R/S-methyl-LXA 4 is the most subtle modification to native LXA 4 and ATL structure with addition of a methyl at carbon Murine TNFa (10 ng/ml) caused a transient infiltration of leukocytes to the air pouch in a O time-dependent fashion with maximal accumulation at 4 h. 15 R/S-methyl-LXA 4 at N nmoles inhibited the TNFa-stimulated recruitment of leukocytes to the air pouch by 62% O (Fig. Inhibition was evident at 1 h, and maximal between 2 h and 4 h. At these CN intervals, a more than 60 reduction in leukocyte infiltration was noted that remained S significantly reduced at 8 h (Fig. 5, insert). Injection of pouches with either vehicle or the analog alone did not cause a significant leukocyte infiltration. Also, inflammatory OO exudates were collected 4 h after injection with vehicle alone, TNFa, 15 R/S-methyl-
LXA
4 alone, or TNFa plus 15 R/S-methyl-LXA 4 and cell types were enumerated. In the six-day pouches given TNFa, PMN constituted the major cell type present within the exudates at 4 h and ranged from 80 to 85% of total cell number. Administration of both R/S-methyl-LXA 4 and TNFca into the six day air pouch cavity inhibited migration of PMN and eosinophils/basophils as well as mononuclear cells (Table Of interest, administration of 15 R/S-methyl-LXA 4 alone evoked a small but statistically significant increase in mononuclear cell influx (Table a result which is consistent with earlier in vitro observations in which specific stimulation of monocyte and inhibition of PMN chemotaxis have been observed (Maddox, M. Hachicha, T. Takano, N.A. Petasis, V.V. Fokin, and C.N. Serhan. 1997. Lipoxin A 4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein linked lipoxin A 4 receptor.
J. Biol. Chem. 272:6972-6978).
-39- I Table I TNFa-induced leukocyte infiltration in murine air pouches: o Inhibitory action of 15 R/S-methyl-LXA 4 t.
Number of leukocytes present in the pouch (x 106) I Eosinophils/ Monocytes/ 00 S Injection Neutrophils Basophils Macrophages STNFa 2.40 0.10* 0.30 0.01* 0.20 0.01 R/S-methyl- 0.98 0.10** 0.13 0.01** 0.10 0.01**
LXA
4 (59.1 (56.0 (50 TNFa 15 R/S-methyl- 0.25 0.01 0.03 0.01 0.14 0.01*
LXA
4 Vehicle 0.30 0.01 0.07 0.01 0.06 0.01 'Air pouches were raised as described in Materials and Methods. Each mouse was injected with 1 ml PBS containing either vehicle (0.1 ethanol), TNFa (10 ng), 15 R/Smethyl-LXA4 (25 nmoles) or TNFa plus 15 R/S-methyl-LXA 4 Leukocyte infiltration was determined 4 h post-injection. Results present the mean SEM of three different mice. Percent inhibition is indicated in parentheses. Statistically different from *vehicleinjected mice and from **TNFa-injected mice (p<0.01).
Cytokine-chemokine profiles Since MIP-2 is the major chemokine involved in recruiting PMN to the air pouch following injection of TNFa ,the action of 15 R/S-methyl-LXA 4 in this TNFa-induced chemokine/cytokine axis was determined. MIP-2 and IL-1 P are important proinflammatory cytokines, and IL-4, IL-10 and IL-13 possess immunomodulatory properties (Isomaki, and J. Punnonen. 1997. Pro- and anti-inflammatory cytokines in O rheumatoid arthritis. Ann. Med. 29:499-507; Volpert. T. Fong, A.E. Koch, J.D.
N Peterson, C. Waltenbaugh, R.I. Tepper, and N.P. Bouck. 1998. Inhibition of angiogenesis o by interleukin 4. J. Exp. Med. 188:1039-1046). Exudates from selected time intervals C were collected and cell-free supernatants assessed for the presence of these murine cytokines. TNFa induced maximal detectable amounts of MIP-2 and IL-1 within tn minutes (not shown). 15 R/S-methyl-LXA 4 (25 nmoles) inhibited TNFa-stimulated 00 MIP-2 and IL-P1 release by 48 and 30 respectively (Fig. 15 R/S-methyl-LXA 4 alone in the air pouch did not stimulate MIP-2 or IL- P1 release. In sharp contrast, R/S-methyl-LXA 4 stimulated the appearance of IL-4 within the exudates. This Sstimulation of IL-4 was observed both in the absence as well as presence of TNFx.
Neither IL-10 nor IL-13 was detected within the pouch exudates. These results demonstrate that administration of 15 R/S-methyl-LXA 4 modified the cytokinechemokine axis in TNFa-initiated acute inflammation, and of interest this re-orientation of the cytokine-chemokine axis paralleled the reduction in leukocyte infiltration.
Several different strategies have been explored in an attempt to attenuate nondesirable action of TNFa in inflammatory diseases and ischemia/reperfusion injury including treatment of patients suffering from rheumatoid arthritis with specific Fc portion of monoclonal antibodies directed against TNFa-receptor Different steroidal and nonsteroidal drugs to alleviate the pain and the severity of inflammatory responses are extensively used (Marriott, M. Westby, and A.G. Dalgleish. 1997.
Therapeutic potential of TNF-a inhibitors old and new. DDT 2:273-282). However, certain clinical settings such as reperfusion injury are still not well controlled, and new therapeutic agents are needed. The present results indicate that LXA 4 and ATL, as evidenced by the actions of their metabolically stable analogs (16-phenoxy-LXA 4 and R/S-methyl-LXA 4 are potent cytokine-regulating lipid mediators that can also impact the course of inflammation initiated by TNFa and IL- 13. These two cytokines are considered to be key components in orchestrating the rapid inflammatory-like events in ischemia/reperfusion (within minutes to hours), and are major cytokines in rheumatoid arthritis and many other chronic diseases. Of interest, in an exudate and skin wound model, 15 R/S-methyl-LXA 4 not only inhibited the TNFa-elicited appearence of IL- 1 and MIP-2, but also concomitantly stimulated IL-4 (Figs. This represents the first observation that lipoxins induce upregulation of a potential "anti-inflammatory" cytokine -41- O such as IL-4. Hence, it is of particular interest that IL-4 inhibits PMN influx in acute antibody-mediated inflammation and inhibits H 2 0 2 production by IFNy-treated human o monocytes (Saleem, Z. Dai, S.N. Coelho, B.T. Konieczny, K.J.M. Assmann, F.K.
Baddoura, and F.G. Lakkis. 1998. IL-4 is an endogenous inhibitor ofneutrophil influx and subsequent pathology in acute antibody-mediated inflammation. J. Immunol.
I160:979-984; Lehn, W.Y. Weiser, S. Engelhom, S. Gillis, and H.G. Remold. 1989.
o0 IL-4 inhibits H202 production and antileishmanial capacity of human cultured ,1 'monocytes mediated by IFN-y. J. Immunol. 143:3020-3024). IL-4 is also an active antitumor agent and most recently was shown to be a potent inhibitor of angiogenesis (Volpert, T. Fong, A.E. Koch, J.D. Peterson, C. Waltenbaugh, R.I. Tepper, and N.P. Bouck. 1998. Inhibition of angiogenesis by interleukin 4. J. Exp. Med. 188:1039- 1046). It is thus likely that the increase in IL-4 levels stimulated by metabolically stable LX analogs may mediate in part some of the in vivo impact of LXA 4 and aspirin-triggered 4 a finding that opens a new understanding of the relationship between "antiinflammatory" cytokines and lipid mediators.
In conclusion,
LXA
4 and aspirin-triggered-LXA4 appear to be involved in controlling both acute as well as chronic inflammatory responses. The results presented here support the notion that aspirin may exert in part its beneficial action via the biosynthesis of endogenous aspirin-triggered-LXA 4 that can in turn act directly on PMN and/or the appearance of IL-4. Thus, LX-ATL can protect host tissues via multi-level regulation ofproinflammatory signals.
-42- References 1. Serhan, J.Z. Haeggstr6m, and C.C. Leslie. 1996. Lipid mediator networks in Scell signaling: update and impact of cytokines. FASEB J. 10:1147-1158.
O2. Weiss, S.J. 1989. Tissue destruction by neutrophils. N. Engl. J. Med. 320:365- 376.
3. Marucha, R.A. Zeff, and D.L. Kreutzer. 1991. Cytokine-induced IL- p gene 00 expression in the human polymorphonuclear leukocyte: transcriptional and post- ,I transcriptional regulation by tumor necrosis factor and IL-1. J. Immunol.
S147:2603-2608.
4. Lloyd, and J.J. Oppenheim. 1992. Poly's lament: the neglected role of the polymorphonuclear neutrophil in the afferent limb of the immune response.
Immunology Today 13:169-172.
Hachicha, P.H. Naccache, and S.R. McColl. 1995. Inflammatory microcrystals differentially regulate the secretion of macrophage inflammatory protein-1 and interleukin- 8 by human neutrophils: A possible mechanism of neutrophil recruitment to sites of inflammation in synovitis. J. Exp. Med.
182:2019-2025.
6. Hansen, P.R. 1995. Role of neutrophils in myocardial ischemia and reperfusion.
Circulation 91:1872-1885.
7. Takano, S. Fiore, J.F. Maddox, H.R. Brady, N.A. Petasis, and C.N. Serhan.
1997. Aspirin-triggered 15-epi-lipoxin
A
4 and LXA 4 stable analogs are potent inhibitors of acute inflammation: Evidence for anti-inflammatory receptors.
J.
Exp. Med. 185:1693-1704.
8. Cliria, and C.N. Serhan. 1995. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc.
Natl. Acad. Sci. USA 92:9475-9479.
9. Lee, C.E. Horton, U. Kyan-Aung, D. Haskard, A.E. Crea, and B.W. Spur.
1989. Lipoxin A 4 and lipoxin B 4 inhibit chemotactic responses of human neutrophils stimulated by leukotriene
B
4 and N-formyl-L-methionyl-L-leucyl-Lphenylalanine. Clin. Sci. 77:195-203.
Serhan, C.N. 1994. Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim. Biophys. Acta 1212:1-25.
-43- 1. Papaylanni, C.N. Serhan, M.L. Phillips, H.G. Rennke, and H.R. Brady. 1995.
Transcellular biosynthesis of lipoxin A 4 during adhesion of platelets and o neutrophils in experimental immune complex glomerulonephritis. Kidney Int.
47:1295-1302.
12. Chavis, 1. Vachier; P. Chanez, J. Bousquet, and P. Godard. 1996. 5(S),1I5(S)- Dihydroxyeicosatetraeloic acid and lipoxin gener ation in human 00 polymorphonuclear cells: dual specificity of 5-lipoxygenase towards endogenous C1 and exogenous precursors. J Exp. Med. 183:1633-1643.
13. Thomas, J.L. Leroux, F. Blotman, and C. Chavis. 1995. Conversion of endogenlous arachidonic acid to 5,1 5-diHETE and lipoxins by polymorphonuclear cells from patients with rheumatoid arthritis. hzfiamm. Res. 44:121-124.
14. Serhan, J.F. Maddox, N.A. Petasis, I. Akritopoulou-Zaflze, A. Papayianni, H.R. Brady, S.P. Colgan, and J.L. Madara. 1995. Design of lipoxin A 4 stable analogs that block transmigration and adhesion of human neutrophils.
Biochemistry 34:14609-146 Gronert, S.P. Colgan, and C.N. Serhan. -199 8 Characterization of human neutrophil and endothelial cell ligand-operated extracellular acidification rate by microphysionietly: impact of reoxygenation. J. Pizarmacol. Exp. Ther. 285:252- 261.
16. Tessier, P.H. Naccache, 1. Clark-Lewis, R.P. Gladue, K.S. Neote, and S.R.
McColl. 1997. Chemnokine networks in vivo: involvement of C-X-C and C-C chemokines in neutrophil extravasation in vivo in response to TNF-ox. J Inmunol.
159:3595-3602.
17. Tsujii, S. Kawano, S. Tsuji, H. Sawaoka, M. Hori, and R.N. DuBois. 1998.
Cyclooxygeriase regulates angiogenesis induced by colon cancer cells. Cell 93 :705-716.
18. Shibuya, N. Ohkohchi, S. Tsukamoto, and S. Satomi. 1997. Tumor necrosis factor-induced, superoxide-mediated neutrophil accumulation in cold ischemic/reperfused rat liver. Hepatology 26:113-120.
19. Jaeschce, A. Farhood, and C.W. Smith. 1990. Neutrophils contribute to ischemialreperfusion injury in rat liver in vivo. FASEB J 4:3355-3359.
Dinarello, C.A. 1996. Biologic basis for interleukin-1 in disease. Blood 87:2095- -44- 2147.
r 21. Fiore, and C.N. Serhan. 1995. Lipoxin A4 receptor activation is distinct from 0 that of the formyl peptide receptor in myeloid cells: inhibition of CD 1/18 expression by lipoxin A 4 -lipoxin A 4 receptor interaction. Biochemisty' 34:16678- 16686.
22. Sin, A.D. Sedgwick, E.P. Chea, and D.A. Willoughby. 1986. Mast cells in c 0 newly formed lining tissue during acute inflammation: a six day air pouch model in the mouse. Ann. Rheum. Dis. 45:873-877.
23. Maddox, M. Hachicha, T. Takano, N.A. Petasis, V.V. Fokin, and C.N.
SSerhan. 1997. Lipoxin A 4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein linked lipoxin A 4 receptor. J.
Biol. Chem. 272:6972-6978.
24. Isomaki, and J. Punnonen. 1997. Pro- and anti-inflammatory cytokines in rheumatoid arthritis. Ann. Med. 29:499-507.
25. Volpert, T. Fong, A.E. Koch, J.D. Peterson, C. Waltenbaugh, R.I. Tepper, and N.P. Bouck. 1998. Inhibition of angiogenesis by interleukin 4. J. Exp. Med.
188:1039-1046.
26. Moreland, S.W. Baumgartner, M.H. Schiff, E.A. Tindall, R.M.
Fleischmann, A.L. Weaver, R.E. Ettlinger, S. Cohen, W.J. Koopman, K. Mohler, M.B. Widmer, and C.M. Blosch. 1997. Treatment of rehumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N.
Engl. J. Med. 337:141-147.
27. Marriott, M. Westby, and A.G. Dalgleish. 1997. Therapeutic potential of TNF-a inhibitors old and new. DDT2:273-282.
28. Saleem, Z. Dai, S.N. Coelho, B.T. Konieczny, K.J.M. Assmann,
F.K.
Baddoura, and F.G. Lakkis. 1998. IL-4 is an endogenous inhibitor of neutrophil influx and subsequent pathology in acute antibody-mediated inflammation.
J.
Immunol. 160:979-984.
29. Lehn, W.Y. Weiser, S. Engelhom, S. Gillis, and H.G. Remold. 1989. IL-4 inhibits H 2 0 2 production and antileishmanial capacity of human cultured monocytes mediated by IFN-y. J. Immunol. 143:3020-3024.
One having ordinary skill in the art will appreciate further features and Sadvantages of the invention based on the above-described embodiments.
Accordingly, the invention is not to be limited by what has been particularly shown O and described, except as indicated by the appended claims. All publications and Ni 5 references cited herein, including those in the background section, are expressly incorporated herein by reference in their entirety.
(I Comprises/comprising and grammatical variations thereof when used in 00 c this specification -are to be taken to specify the presence of stated features, S integers, steps or components or groups thereof, but do not preclude the 0 10 presence or addition of one or more other features, integers, steps, components c or groups thereof.
Claims (8)
1. A method for modulating seborrheic dermatitis, pustular dermatosis or dandruff associated with TNFa initiated polymorphoneutrophil (PMN) 5 inflammation in a subject, comprising (N 00 administering to the subject an effective anti-TNFx amount of a lipoxin N analog having the formula: R 2 HO OH X O H R 5 R3 R6 Y, wherein X is R 1 OR 1 or SR 1 wherein R, is a hydrogen atom; (ii) an alkyl of 1 to 8 carbon atoms, inclusive, which may be straight chain or branched; (iii) a cycloalkyl of 3 to 10 carbon atoms; (iv) an aralkyl of 7 to 12 carbon atoms; phenyl; (vi) substituted phenyl i\ Zii /iii O wherein Zi, Zii, Ziii, Ziv and Zv are each independently selected from -NO 2 c -CN, -SO 3 H, a hydrogen atom, halogen, methyl, -ORx, wherein Rx is 1 c to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl; 00 0 5 (vii) a detectable label molecule; or (viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, n inclusive; oo 00 wherein RT is a hydrogen atom; 0 10 (ii) an alkyl of 1 to 8 carbon atoms, inclusive, which may be straight C- chain or branched; (iii) a cycloalkyl of 3 to 10 carbon atoms; (iv) an aralkyl of 7 to 12 carbon atoms; phenyl; (vi) substituted phenyl Ziii Z Zi, Zv Ziv wherein Zi, Zii, Ziii, Ziv and Zv are each independently selected from -NO 2 -CN, -SO 3 H, a hydrogen atom, halogen, methyl, -ORx, wherein Rx is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl; (vii) a detectable label molecule; or (viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive; wherein Q1 is SO 2 or provided when Q 1 is CN, then X is absent; wherein Q3 and Q4 are each independently O, S or NH; wherein one of R 2 and R 3 is a hydrogen atom and the other is H; O an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight C chain or branched; a cycloalkyl of 3 to 6 carbon atoms, inclusive; an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight 00 0 5 chain or branched; or RaQ 2 Rb wherein Q2 is or wherein Ra is alkylene of 0 to 6 carbon atoms, inclusive, which may be straight chain or branched and wherein Rb 00 0 is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or N branched, provided when Rb is 0, then Rb is a hydrogen atom; C 10 wherein R 4 is N H; an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched; wherein R 5 is Zi Z, Zv Ziv wherein Zi, Zin, Zi, Ziv and Zv are each independently selected from -NO 2 -CN, -SO 3 H, a hydrogen atom, halogen, methyl, -ORx, wherein Rx is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group; wherein Y 1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CHaZb where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen; wherein R 6 is H; an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched; O0 O oO OIn oo 00 wherein T is O or S, and pharmaceutically acceptable salts thereof, such that seborrheic dermatitis, pustular dermatosis or dandruff associated with TNFa initiated polymorphoneutrophil (PMN) inflammation is modulated in a subject.
2. A method for modulating seborrheic dermatitis, pustular dermatosis or dandruff associated with TNFa initiated cytokine inflammation in a subject, comprising administering to the subject an effective anti-TNF( amount of a lipoxin analog having the formula: R2 HO OH x R, Y, chain wherein X is R 1 OR 1 or SR wherein R 1 is a hydrogen atom; (ii) an alkyl of 1 to 8 carbon atoms, inclusive, which may be straight or branched; (iii) a cycloalkyl of 3 to 10 carbon atoms; (iv) an aralkyl of 7 to 12 carbon atoms; phenyl; (vi) substituted phenyl Zi Zi Z O wherein Zi, Zii, Ziii, Ziv and Zv are each independently selected from -NO 2 Cl -CN, -SO 3 H, a hydrogen atom, halogen, methyl, -ORx, wherein Rx is 1 c to 8 carbon atoms, inclusive, which may be a straight chain or branched, and Shydroxyl; 00 S 5 (vii) a detectable label molecule; or (viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive; 00 wherein RT is a hydrogen atom; 0 10 (ii) an alkyl of 1 to 8 carbon atoms, inclusive, which may be straight c chain or branched; (iii) a cycloalkyl of 3 to 10 carbon atoms; (iv) an aralkyl of 7 to 12 carbon atoms; phenyl; (vi) substituted phenyl ZI Zi Z\ /Z ii Ziii Z Ziv wherein Zi, Zii, Ziii, Zi, and Z are each independently selected from -NO 2 -CN, -SO 3 H, a hydrogen atom, halogen, methyl, -ORx, wherein Rx is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl; (vii) a detectable label molecule; or (viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive; wherein Q1 is SO 2 or provided when Q1 is CN, then X is absent; wherein Q3 and Q 4 are each independently O, S or NH; wherein one of R 2 and R 3 is a hydrogen atom and the other is H; r-- O an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight 6 c chain or branched; a cycloalkyl of 3 to 6 carbon atoms, inclusive; an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight 00 0 5 chain or branched; or RaQ 2 Rb wherein Q 2 is or wherein Ra is alkylene of 0 to 6 carbon atoms, inclusive, which may be straight chain or branched and oo 00 wherein Rb is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight Schain or branched, provided when Rb is 0, then Rb is a hydrogen atom; a 10 wherein R 4 is N H; an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched; wherein R 5 is Zi ZiI Zv Zi wherein Zi, Zn, Ziii, Zi, and Zv are each independently selected from -NO 2 -CN, -SO 3 H, a hydrogen atom, halogen, methyl, -ORx, wherein Rx is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group; wherein Y 1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CHaZb where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen; wherein R 6 is H; an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched; O0 O In 00 OO wherein T is O or S, and pharmaceutically acceptable salts thereof, such that seborrheic dermatitis, pustular dermatosis or dandruff associated with TNFa initiated cytokine inflammation is modulated in a subject.
3. A method for modulating seborrheic dermatitis, pustular dermatosis or dandruff associated with TNFu initiated IL-1p inflammation in a subject, comprising administering to the subject an effective anti-TNFc amount of a lipoxin analog having the formula: R 2 R6 Y, chain wherein X is R1, OR1, or SR, wherein R, is a hydrogen atom; (ii) an alkyl of 1 to 8 carbon atoms, inclusive, which may be straight or branched; (iii) a cycloalkyl of 3 to 10 carbon atoms; (iv) an aralkyl of 7 to 12 carbon atoms; phenyl; (vi) substituted phenyl 54 O wherein Zi, Zii, Ziii, Ziv and Z are each independently selected from -NO 2 cl -CN, -SO 3 H, a hydrogen atom, halogen, methyl, -ORx, wherein Rx is 1 t to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl; 00 0 5 (vii) a detectable label molecule; or (viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive; oo 00 wherein RT is a hydrogen atom; 0 10 (ii) an alkyl of 1 to 8 carbon atoms, inclusive, which may be straight C chain or branched; (iii) a cycloalkyl of 3 to 10 carbon atoms; (iv) an aralkyl of 7 to 12 carbon atoms; phenyl; (vi) substituted phenyl Zi\ /Z *Ziii Z Zi wherein Zi, Zii, Zij, Ziv and Zv are each independently selected from -NO 2 -CN, -SO 3 H, a hydrogen atom, halogen, methyl, -ORx, wherein Rx is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl; (vii) a detectable label molecule; or (viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive; wherein Q 1 is SO 2 or provided when Q 1 is CN, then X is absent; wherein Q3 and Q4 are each independently O, S or NH; wherein one of R 2 and R 3 is a hydrogen atom and the other is H; O an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight N chain or branched; c a cycloalkyl of 3 to 6 carbon atoms, inclusive; an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight oO chain or branched; or RaQ 2 Rb wherein Q2 is or wherein Ra is alkylene of 0 to 6 carbon atoms, inclusive, which may be straight chain or branched and wherein Rb 00 is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or Sbranched, provided when Rb is 0, then Rb is a hydrogen atom; wherein R 4 is N H; an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched; wherein R 5 is Zi\ ii Z Z wherein Zi, Zi, Ziii, Ziv and Zv are each independently selected from -NO 2 -CN, -SO 3 H, a hydrogen atom, halogen, methyl, -ORx, wherein Rx is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group; wherein Y 1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CHaZb where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen; wherein R 6 is H; an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched; r- O wherein T is O or S, and pharmaceutically acceptable salts thereof, such N that seborrheic dermatitis, pustular dermatosis or dandruff associated with TNFo 3 initiated IL-1P inflammation is modulated in a subject. 00
4. A method for modulating seborrheic dermatitis, pustular dermatosis or dandruff associated with TNFc initiated polymorphoneutrophil (PMN) Sinflammation in a subject, comprising oO 00 administering to the subject an effective anti-TNFa amount of a lipoxin c analog having the formula 0O C HO0 ,OH OR OH wherein R is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof, such that seborrheic dermatitis, pustular dermatosis or dandruff associated with TNFa initiated polymorphoneutrophil (PMN) inflammation is modulated in a subject.
5. A method for modulating seborrheic dermatitis, pustular dermatosis or dandruff associated with TNFa initiated cytokine inflammation in a subject, comprising administering to the subject an effective anti-TNFa amount of a lipoxin analog having the formula OC HO OH OR 00 H OH 00 ci wherein R is a hydrogen atom, a pharmaceutically acceptable ester and O pharmaceutically acceptable salts thereof, such that seborrheic dermatitis, c 5 pustular dermatosis or dandruff associated with TNFa initiated cytokine inflammation is modulated in a subject.
6. A method for modulating seborrheic dermatitis, pustular dermatosis or dandruff associated with TNFo initiated IL-13 inflammation in a subject, comprising administering to the subject an effective anti-TNFa amount of a lipoxin analog having the formula 0 HO, ,OH OR OH wherein R is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof, such that seborrheic dermatitis, pustular dermatosis or dandruff associated with TNFa initiated IL-13 inflammation is modulated in a subject. O
7. A method for modulating seborrheic dermatitis, pustular dermatosis or Sdandruff according to any one of claims 1 to 6 substantially as hereinbefore c described with reference to the Examples. 00
8. Use of a lipoxin analog having the formula as described in any one of claims 1 to 6 for the manufacture of a medicament for the modulation of t r seborrheic dermatitis, pustular dermatosis or dandruff. 00oo (N BRIGHAM AND WOMEN'S HOSPITAL WATERMARK PATENT TRADE MARK ATTORNEYS 290 BURWOOD ROAD HAWTHORN VICTORIA 3122 AUSTRALIA P20172AU01
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007214312A AU2007214312B2 (en) | 1999-03-18 | 2007-08-30 | Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12520599P | 1999-03-18 | 1999-03-18 | |
US60/125205 | 1999-03-18 | ||
AU38806/00A AU775140B2 (en) | 1999-03-18 | 2000-03-14 | Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response |
PCT/US2000/006582 WO2000054767A1 (en) | 1999-03-18 | 2000-03-14 | Use of lipoxin compounds for inhibiting of tnf-(alfa) initiated neutrophil response |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU38806/00A Division AU775140B2 (en) | 1999-03-18 | 2000-03-14 | Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2007214312A Division AU2007214312B2 (en) | 1999-03-18 | 2007-08-30 | Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2004222825A1 AU2004222825A1 (en) | 2004-11-25 |
AU2004222825B2 true AU2004222825B2 (en) | 2007-05-31 |
Family
ID=38171229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2004222825A Ceased AU2004222825B2 (en) | 1999-03-18 | 2004-10-22 | Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2004222825B2 (en) |
-
2004
- 2004-10-22 AU AU2004222825A patent/AU2004222825B2/en not_active Ceased
Non-Patent Citations (5)
Title |
---|
Gewirtz AT, et al. J Clin * |
Invest. 1998 May 1;101(9):1860-9. * |
Serhan CN, et al. Adv Exp Med Biol. 1999;469:287-93. * |
Takano T, et al. J Clin Invest. 1998 Feb 15;101(4):819-26. * |
Takano T, et al. J Exp Med. 1997 May 5;185(9):1693-704. * |
Also Published As
Publication number | Publication date |
---|---|
AU2004222825A1 (en) | 2004-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU775140B2 (en) | Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response | |
US8119691B2 (en) | Method for treating airway hyper-responsiveness with lipoxin analogs | |
US7227031B2 (en) | Prevention of neutrophil recruitment | |
AU2009201390B2 (en) | A novel approach to antimicrobial host defense against gram-negative infections | |
AU2004222825B2 (en) | Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response | |
AU2007214312B2 (en) | Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response | |
EP1616566A1 (en) | Lipoxin compounds for treating TNF-alpha initiated inflammation | |
EP1911448B1 (en) | Lipoxins and Aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases | |
AU2004235617B2 (en) | Lipoxin compounds and their use | |
AU2012203640A1 (en) | Lipoxins and Asprin-Triggered Lipoxins and their Stable Analogs in the Treatment of Asthma and Inflammatory Airway Diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE APPLICANT FROM BRIGHAM AND WOMEN S HOSPITAL TO THE BRIGHAM AND WOMEN S HOSPITAL, INC. |
|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |